Gout: A Clinical Update. Why talk about Gout? Why talk about Gout? Populations at risk: Why is Gout Less Common in Women? US Gout Population: 2009
|
|
- Franklin Joel Blankenship
- 5 years ago
- Views:
Transcription
1
2 Gout: A Clinical Update Peng Thim Fan, MD, FACP Clinical Professor of Medicine Division of Rheumatology David Geffen School of Medicine at UCLA Why talk about Gout? Large increase in gout in the last 20 years % in the last 30 years 1.56 million men, 550,000 women (1992 self-reported) 3 million self-reported A&R 1/08 Recent estimate 8.3 million Now the most common inflammatory arthritis in men 7 Why talk about Gout? Aging population contributes to problem Polypharmacy, co-morbidities, reduced drug clearance, increased toxicity profile Wide use of diuretics in patients with renal insufficiency and/or congestive heart failure Altered dietary trends, rising prevalence of obesity, metabolic syndrome, end-stage renal disease Transplant patients - cyclosporine Renewed interest because of new and effective medications US Gout Population: 2009 Estimated number of affected persons in the US 8.3 million million , ,000 (1 3%) 4 Patients with Gout Treated With Allopurinol or Febuxostat 1. NHANES Halpern R, et al. Curr Med Res Opin. 2009,25: Harris Interactive poll: A Survey of Patients with Gout, 2006 Poor Urate Control / Progressive Symptoms Chronic Gout Refractory to Conventional Therapy* Populations at risk: The risk of gout is a consequence of hyperuricemia Risk of initial gout attack: Serum urate 7.0 to 8.9 mg/dl* Annual attack rate 0.1% 5-year incidence 3% Serum urate > 9.0 mg/dl Annual incidence 4.9% 5-year incidence 22% After the first attack of gout the risk is of future attacks is higher Why is Gout Less Common in Women? Adult men reach maximal serum urate at puberty and the level rises little with age Average 5-6 mg/dl Women have lower serum urate before menopause related to fractional urate excretion due to estrogen Average 1.0 to 1.5 mg/dl lower than males After menopause with loss of estrogenic influence serum urate rapidly catches up with men Risk of gout is 6x higher than before menopause One-third of new cases of gout after age 65 are women Punzi L, So A. Curr Med Res Opin 2013;Suppl 3: 3-8
3 Populations at risk: Pacific Islanders Hawaii, Tahiti, New Zealand Maori, Filippino High prevalence in the Hmong people Minnesota, Central California (onset age 37; mean uric acid 9.1 mg/dl) Defect is underexcretion by the kidneys 1. Krishna, J Rheum 2008;35: Maloney, J Urol 2005;173: Wahedduddin, J Clin Rheum 2010;16:262 Clinical Setting of Typical Gout 40-year-old male History of CHD, hypertension, hypercholesterolemia Several episodes of pain in his left foot and ankle in the past lasting several days Severe pain and swelling in the left big toe since yesterday morning* Erythema and swelling left first MTP joint Clinical Setting of Typical Gout Risk of gout attacks at night and early morning is 2.4 x higher than daytime 724 patients internet study Possible reasons Nocturnal dehydration Lower body temperature dip in cortisol level Sleep apnea with nucleotide turnover generates purines Choi et al. Arth Rheum 2015; 67: Clinical Setting of Typical Gout First attack monoarticular 80% Great toe joint affected 75% Polyarticular gout 40% (with full examination) Lawry GV 2nd, Fan PT, Bluestone R. Medicine 188;67:335 Great toe Forefoot Ankle Heel Knee Wrist Finger Elbow Risk Factors and Co-morbidities Coronary heart disease Hypertension Hyperlipidemia Obesity* Anemia (<13.5 m; <12 w)** Recent weight gain of 30 lbs High alcohol consumption particularly beer and distilled spirits High fructose corn syrup in soft drinks increases risk Increases AMP degradation to ATP Diet drinks are safe Is cane sugar safe? What tests should we perform? CBC with differential Comprehensive metabolic panel BUN, creatinine Liver function tests Glucose ESR, C-reactive protein Uric acid Uric acid normal (< 7.0 mg/dl) in up to 50% during acute attack! Repeat serum urate in 2 weeks after acute attack * Campion EW. Am J Med 1987;82:421
4 Are Radiographs of Any Use? Well-marginated punched out bone erosions confirm gout Strongly indicate tophi Amorphous calcium deposits and often fine stippled calcification, usually around the sesamoid bones suggest a different diagnosis Calcific periarthritis Periosteal bone reaction suggests osteomyelitis or psoriatic dactylitis Is Joint Fluid Examination Necessary? Examination of joint fluid under polarized light is the BEST way to diagnose gout Serum urate is normal in 50% during acute gout, 30% even in polyarticular gout Negatively birefringent crystals under a first-order compensator Hydroxyapatite shows up as amorphous globules with variable birefringence What if you cannot get joint fluid? Our patient s presentation is classic Reasonable to treat as gout If he does not respond to an NSAID in 3 days send him to a rheumatologist or orthopedic surgeon for joint aspiration Treatment for Acute Gout Start with rapidly-acting NSAID: indomethacin 100mg then 50mg q8h x 3-4 days Reduce to 50mg twice a day for 1 week Other rapidly acting NSAID may work as well: ibuprofen, naproxen, diclofenac Avoid long-acting NSAIDs: piroxicam, oxaprozin COX-2 inhibitors may work: etoricoxib Add PPI if GI history Even under ideal conditions between 100,000 to 300,000 of 5 million cases in the US will be treatment failures Treatment for Acute Gout Colchicine 1mg followed by 0.6mg hourly x 6 may work Predictably causes diarrhea, vomiting or both A better scheme is 1.2mg at diagnosis followed by 0.6mg 1 hour later and then no more colchicine for 24 hours * Avoid IV colchicine (not available anymore) * Terkeltaub RA, Furst DE, Bennett K, et al. Arthritis Rheum 2010; 62:1060. Treatment for Acute Gout Intra-articular corticosteroid or systemic works well Prednisone 30mg daily x 5 days Rebound of gout does NOT occur Useful in patients with creatinine > 2.0 mg/dl Or surgical patients Don t start urate-lowering treatment during an acute attack of gout (? Dogma) Taylor TH, Mecchella JN, Larson RJ, et al. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125:1126.
5 Are there Effective Non-drug Options? For first attack, treat pain and swelling 10-lb weight loss effective if overweight Strict purine diet is unpalatable with poor long-term compliance lowers serum urate by only 1 mg/dl Reasonable option Switch to low-fat dairy products Eat less red meat and fish Restrict calories, use complex CHO, reduce sat fat Are there Effective Non-drug Options? 2 glasses of wine a day NOT associated with risk Change diuretic treatment for hypertension to alternative agent; losartan has uricosuric effect HCTZ: serum urate by 0.8 mg/dl; less if renal compromise 81mg enteric-coated aspirin daily OK: raises serum urate by 0.3 mg/dl Supplemental vitamin C at 1500mg/d lowers gout risk 50% When should we start urate-lowering? Excessive intake Endogenous overproduction Underexcretion (90%) (10%) HYPERURICEMIA Tissue deposition Gout Renal Stones CV events Do people with gout have kidney stones? NHANES III (2002): 10 million people had kidney stones (5.7% of popn); 5.1 million (2.7%) reported gout Of those with stones 8.6% had a history of gout 13.9% of patients with gout reported kidney stones RR after all adjustments for stones in gout patients was 1.49 ( ) Kramer HM, Curhan G Am J Kidney Dis. 2002;40(1):37. Health Professionals Follow-up Study (2003): patients with stones not at higher risk for gout RR 1.05 ( ) Kramer HJ, Choi HK, et al. Kidney Int. 2003;64(3):1022. When should we start urate-lowering? Gout: Metabolic Disease of Purine Metabolism If serum urate is not lowered 62% another attack in next year 78% within 2 years 93% within 10 years If urate level > 9.0 mg/dl then 80% recurrent attack in the next 12 months If urate level is below 6.0 mg/dl 86% have no recurrence within 1 year and maintained during 3 years Hypoxanthine Purines 1 Cell breakdown & diet xanthine oxidase allopurinol 2 febuxostat Xanthine Conventional Therapy xanthine oxidase allopurinol 2 febuxostat Uric Acid probenecid 2 Arthritis Care & Research Volume 51, Issue 3, pages , 3 JUN 2004 DOI: /art Becker M, Jolly M. In: Koopman WJ, Moreland LW (eds). A Textbook of Rheumatology. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman, M in Rheumatology. 5 th ed. Philadelphia, PA: Elsevier; 2011: Urinary Excretion
6 How should we lower serum urate? Probenecid 250mg twice a day for 1 month then increase to mg twice a day over next 2 months Encourage fluid intake Maximum 1500mg twice a day Each aspirin tablet of 325mg will nullify the effect of 500mg of probenecid Not effective if creatinine clearance is under 50 ml/min Do not use urinary uric acid > 800mg / 24 hours Avoid in patients with sulfa allergy May be used together with a xanthine oxidase inhibitor for additive effect add to allopurinol or febuxostat How should we lower serum urate? Allopurinol Start with 100mg daily and increase every 2-4 weeks to maximum 800mg daily Even though allopurinol is eliminated by renal excretion higher doses of mg daily are safe in CKD Get urate below 6 mg/dl: don t stop at 300mg/d!!! At 300mg daily only 9% of patients with urate >10 mg/dl achieves a serum urate < 6.0 mg/dl Allopurinol Side Effects Rash, diarrhea, drug fever, leukopenia, thrombocytopenia 5% Allopurinol hypersensitivity syndrome is very rare but 25% mortality Severe rash, fever, hepatitis, eosinophilia, acute renal failure Reported in patients with renal insufficiency started on allopurinol 300mg daily More common in asymptomatic hyperuricemia Allopurinol Side Effects HLA-B*5801 allele present in 100% of Han Chinese with Stevens-Johnson syndrome or toxic epidermal necrolysis Confirmed in Koreans but association not seen in Japanese population Perform HLA-B*5801 in Han Chinese, Thai, and Koreans with CKD 3 or worse Hung, PNAS 2005; 102:4134 How should we lower serum urate? Febuxostat non-purine xanthine oxidase inhibitor 40mg once daily is recommended starting dose after 2 weeks increase to 80mg daily if serum uric acid is >6 mg/dl T ½ is 5-8hrs, only 3% excreted by the kidneys, extensively metabolized by the liver: no adjustment for renal insufficiency Do not use together with allopurinol no additive benefit How should we lower serum urate? Always provide anti-inflammatory prophylaxis for 6 months when starting a urate lowering agent
7 Strategy for Successful Long-term Treatment Wait a month before lowering uric acid (? Dogma) Check uric acid at least twice a year Always give a prophylactic agent: colchicine 0.6 mg once or twice a day for 6 months beyond reaching target urate of 6.0 mg/dl Colchicine 0.6mg daily may reduce CV events by 49% and all-cause mortality by 73%. (Solomon. Ann Rheum Dis 2015doi: /annrheumdis ) NSAIDs may be used; short-term prednisone trial for flares Pegloticase: Mechanism of Action Hypoxanthine Purines 1 Cell breakdown & diet xanthine oxidase 2 Xanthine xanthine oxidase 2 Urate Pegloticase + Uricase H 2 O + O 2 H 2 O 2 Allantoin Use combination allopurinol and probenecid for tophaceous gout Newer agents febuxostat novel non-purine xanthine oxidase inhibitor IV polyethylene glycol uricase (pegloticase) 8mg IV q2w Urinary Excretion 1. Becker M, Jolly M. In: Koopman WJ, Moreland LW (eds). A Textbook of Rheumatology. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman, M in Rheumatology. 5 th ed. Philadelphia, PA: Elsevier; 2011: KRYSTEXXA (pegloticase) Full Prescribing Information. Savient Pharmaceuticals, Inc. September Hershfield MS, et al. Proc Natl Acad Sci. U S A. 2010;107: Urinary Excretion Pegloticase: For Chronic Tophaceous Gout Indicated for patients who failed or are intolerant to allopurinol and febuxostat Given at 8mg every 2 weeks as an IV infusion over 120 minutes Risk of infusion reaction and anaphylaxis can be reduced if treatment is stopped for patients who do not achieve a serum uric acid of < 6mg/dl either once or 2 consecutive infusions Should not be used with other urate-lowering therapy High risk of gout flares needs prophylaxis with colchicine or NSAID Leisured: A URAT1 Inhibitor Outcomes Uric Acid <6 mg/dl Febuxostat 40 mg/d 67% Febuxostat 80 mg/d 56% Febuxostat 40 mg/d + lesinurad 400 mg/d Febuxostat 40 mg/d + lesinurad 600 mg/d Febuxostat 80 mg/d + lesinurad 400 mg/d Febuxostat 80 mg/d + lesinurad 600 mg/d 100% 82% 100% 100% 100% 100% 100% 100% Uric Acid < 5 mg/dl Fleischmann R et al Rheumatology 2014;53: Should we treat asymptomatic hyperuricemia? Make sure it is asymptomatic! No renal stones, gouty tophi, suspicious gout history If truly asymptomatic: don t treat.? Treat if significant renal impairment? Treat if uric acid level is >11 mg/dl or 24-hour urine urate >1000mg Still controversial how much hyperuricemia contributes to hypertension, CAD or diabetes Hyperuricemia 1. co-factor in Na+ sensitive hypertension J Hyp Independent risk factor for CVD. Should we treat asymptomatic hyperuricemia? Allopurinol halves the incidence of non-fatal acute MI Spanish study of 3171 non-fatal acute MI controls Current use allopurinol- risk was 0.82% Controls 1.03% RR 0.52 (0.33 to 0.83) Men 0.44; women 0.90 ns. Only seen with doses 300mg/d and >180 days 33% of patients had uric acid but not gout 54% had gout In patients who had previous MI RR 0.16 De Abajo F, et al. Heart online Jan 2015
8 Gout: The future Understanding gout Recognition of Pathogens by Toll-like Receptors Bacteria Yeast Viruses Protozoa Uropath Gram -ve Gram +-ve Mycobacteria All All RSV All T. cruzi. bacteria LPS PGN lipoproteins CpG Flagellin Zymosan protein poly-c ssrna GPI anchors lipoproteins GIPLs Host Hsp60 FN frags TLR-4/4 TLR-2/6 TLR-6/1 TLR-9/? TLR-5/? TLR11 TLR-2/? TLR-4/4 TLR-3/? TLR-7/8 TLR-2/? TLR-4/4 MyD88 NFĸB JNK p38 TLRs mediate innate immune response Found on macrophages, neutrophils and dendritic cells Recognize distinct pathogen-associated molecular patterns conserved in microbes, eg, lipopolysacharides, lipoproteins,viral ds RNA Stimulate NF-κB associated cytokines, eg, TNF, IL-1, IL-8 via activation of stress kinases Shares signaling apparatus with IL-1R adapter protein MyD88 MSU crystals activate complement and generates the C5b-C9 membrane attack complex C5 is cleaved on crystal surface C5a generated promotes the C5b-C9 Membrane attack complex Endothelial cells activated IL-8 release Liu-Bryan R, Terkeltaub R. Arthritis Rheum 2006; 54:383 IL-1 inhibitors very effective in treating Gout Anakinra IL-1R antagonist 100mg SQ daily x 3d Canakinumab mab to IL-1β single 150mg SQ Rilonacept traps IL-1 single 320mg SQ Canakinumab is the most effective, better than a single triamcinolone acetonide injection of 40mg IM But 5000x more expensive!! Sivera F1, Wechalekar MD, Andrés M, Buchbinder R, Carmona L. Cochrane Database Syst Review September 2014 References 1. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, Ann Rheum Dis 2005; 64: Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008; 20: Nakayama DA, Barthelemy C, Carrera G, et al. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984; 27: Lawry GV 2nd, Fan PT, Bluestone R. Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore) 1988; 67:335. References 1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007; 3: Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey Arthritis Rheum 2011; 63:3136.
9 References 1. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol 2009; 36: McQueen FM, Doyle A, Dalbeth N. Imaging in the crystal arthropathies. Rheum Dis Clin North Am 2014; 40: Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007; 46: Rettenbacher T, Ennemoser S, Weirich H, et al. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol 2008; 18: Agudelo CA, Weinberger A, Schumacher HR, et al. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979; 22:559. References 1. Schumacher HR, Smolyo AP, Tse RL, Maurer K. Arthritis associated with apatite crystals. Ann Intern Med 1977; 87: Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006; 32: Zhang W, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: Khanna D, et al American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447.
1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout
Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.
More informationGout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy
Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No
More informationOBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE
GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when
More informationGout -revisited. Shrenik Shah
Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European
More informationGout Treatment Guidelines
Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,
More informationCase presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg
GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies
More informationA Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.
A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally
More informationGout: Update in therapeutics
Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?
More informationGout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA
Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PEGLOTICASE KRYSTEXXA 37154 GUIDELINES FOR USE 1. Does the patient have a diagnosis of symptomatic chronic gout (prior to initiating Krystexxa therapy) with clinical
More informationPodcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam. Howard J. Sachs, MD
Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded Lecture Series): Gout for the
More informationGout Hanan Abdel Rehim
Review article 35 Gout Hanan Abdel Rehim Department of Internal Medicine, Kasr-Al Aini School of Medicine, Cairo University, Cairo, Egypt Correspondence to Hanan Abdel Rehim, MD, 11 Ismaiel Wahby Street,
More informationAn update on the management of gout
An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence
More informationUpdate on Gout for GPs
Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis
More informationGout A rapid review. Jeremy Jones
Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout
More informationGOUT. Dr Krishnan Baburaj West herts NHS Trust
GOUT Dr Krishnan Baburaj West herts NHS Trust podagra Gout A disease of kings, the king of diseases History Louis XIV Emperor Augustus Henry VIII Introduction Gout an inflammatory arthritic condition that
More informationCHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:2 GOUT BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY DEFINITION Gout is defined as a peripheral arthritis, resulting from the deposition of MSU crystals
More informationManaging Gout A Review of the Research for Adults
Managing Gout A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional* has said that you have gout. You are age 18 or
More informationRheumatology Cases for the Internist
Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School
More informationGout: Develop treatment plan in William Jones, MS, RPh
Gout: Develop treatment plan in 2013 William Jones, MS, RPh (wnjones49@cox.net) Objectives Describe acute gouty arthritis Tx Describe Tx of chronic gouty arthritis. Define the target serum uric acid concentration
More informationCrystal induced arthropathies. Dr. Amitesh Aggarwal
Crystal induced arthropathies Dr. Amitesh Aggarwal 1 Crystal induced Arthropathies Gout Pseudogout Debilitating illnesses; Recurrent episodes of pain and joint inflammation; Formation and deposition of
More informationDrugs Used to Treat Gout. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used to Treat Gout Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Gout is a metabolic disease characterized by recurrent episodes of acute arthritis
More informationAchieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP
Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services
More informationEnhanced Primary Care Pathway: Gout
Enhanced Primary Care Pathway: Gout 1. Focused summary of gout relevant to primary care Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout
More informationMEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011
Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY PREAUTHORIZATION REQUIRED Note: Requests for pegloticase
More informationCOMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT
Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF
More informationGout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting
Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia
More information3/2/2014. Got Gout? Get a Plumber. Objectives. Disclosures
Got Gout? Get a Plumber. Heidi Garcia, PA-C Department of Rheumatology Division of Internal Medicine Mayo Clinic Arizona 2013 MFMER slide-1 Objectives Recall some of the history of Gout. Describe the pathophysiology
More informationCOPYRIGHT. Update in Internal Medicine December 4, 2016
Update in Internal Medicine December 4, 2016 Fadi Badlissi, MD, MSc Director of the Musculoskeletal Medicine Unit The Orthopedic Department & Rheumatology Division Beth Israel Deaconess Medical Center
More informationUloric Step Therapy Program
Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand
More informationRheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy
Rheumatoid arthritis, seronegative spondylarthritides and gout György Nagy Dec 4, 2017 Rheumatoid arthritis Rheumatoid arthritis Chronic, progressive, autoimmune disorder of the joints with extra-articular
More informationLecture 8 Gout Hinch. Pathogenesis of acute attacks
Gout: disease characterized by deposition of monosodium crystals in soft tissues (cartilage, tendons, bursa) recurrent episodes of acute joint pain & inflammation Pathogenesis of acute attacks Epidemiology:
More informationGOUT IN THE ELDERLY. Learning Objectives. Disclosure. Geriatric Grand Rounds. Geriatric Grand Rounds
Visit web sites: Tuesday, June 2, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this event
More informationEssence of the Revised Guideline for the Management of Hyperuricemia and Gout
Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of
More informationWhat will happen in the future? How will gout be diagnosed? How is gout treated? prevent
Rheumatology Day Unit Dr J Hamilton 0191 4458359 0191 4455240 (9-5 Mon-Fri) Dr C Heycock 0191 4452198 Answer phone on 24hours Dr C Kelly 0191 4452193 Dr V Saravanan 0191 4456055 Dr M Rynne 0191 4458359
More informationGOUT & PSEUDOGOUT OPSC 2018 HOWARD L. FEINBERG, D.O., F.A.C.O.I.., F.A.C.R.
GOUT & PSEUDOGOUT OPSC 2018 HOWARD L. FEINBERG, D.O., F.A.C.O.I.., F.A.C.R. Everything in excess is opposed by nature Eunuchs do not take the gout, nor become bald. GOUT Hyperuricemia is not gout Gout
More informationLong-term Treatment of Gout: New Opportunities for Improved Outcomes
Long-term Treatment of Gout: New Opportunities for Improved Outcomes Paul P. Doghramji, MD, FAAFP CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Make a presumptive diagnosis of gout based on history
More informationCurrent treatment options for acute and chronic gout
DRUG REVIEW n Current treatment options for acute and chronic gout Kelsey Jordan FRCP and Andrew Jeffries PGDip, MRCP Gout is the only curable form of arthritis, yet only a third of patients with chronic
More informationKrystexxa (pegloticase) Document Number: IC-0158
Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGOUT disease spectrum including
GOUT disease spectrum including *hyperuricemia, *recurrent attacks of acute arthritis associated with monosodium urate crystals in leukocytes found in synovial fluid, *deposits of monosodium urate crystals
More informationDose of celecoxib in gout attack attack
Dose of celecoxib in gout attack Gout is a disease characterized by an abnormal metabolism of uric acid, resulting in an excess of uric acid in the tissues and blood. People with gout either produce too
More informationDiagnosis and Management of Gout in 2011
October 18, 2011 Early and accurate gout diagnosis and disease management are essential. Making the clinical diagnosis takes into consideration the differential diagnosis supported by the use of clinical,
More informationAcute hot swollen joint. Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist
Acute hot swollen joint Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist Acute monoarthritis: differential diagnosis Septic arthritis Crystal arthritis (gout, pseudogout) Haemarthrosis
More informationGout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017
Gout: Let s Be Crystal Clear Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationCrystal-Induced Arthritis. Rajesh Kataria, D.O. Southern Ohio Rheumatology
Crystal-Induced Arthritis Rajesh Kataria, D.O. Southern Ohio Rheumatology Disclosures Speaker: Rajesh Kataria, D.O. Relationships with commercial interests: Speakers Bureau - Horizon Presentation will
More informationDrugs for Gout, osteoarthritis and osteoporosis
MMS Pharmacology Lecture 3 Drugs for Gout, osteoarthritis and osteoporosis Dr Sura Al Zoubi Revision Gout The term gout describes a disease spectrum including hyperuricemia, recurrent attacks of acute
More informationCase Report Refractory Gout Attack
Case Reports in Medicine Volume 2012, Article ID 657694, 4 pages doi:10.1155/2012/657694 Case Report Refractory Gout Attack Simone Fargetti, Claudia Goldenstein-Schainberg, Andressa Silva Abreu, and Ricardo
More informationImplementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices
Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Gout: Diagnosis and Management Practice Pointers by MATTHEW R. NOSS, DO, MSEd, U.S. Army Health Clinic,
More informationSubject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s):
Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13 Policy Number: MCP-138 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Gout and Pseudogout Wayne Blount MD Speaker has no disclosures
More informationInitiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial
BRIEF OBSERVATION Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial Thomas H. Taylor, MD, a,b,c John N. Mecchella, DO, b,c Robin J. Larson, MD, a,b
More informationMONOSODIUM URATE CRYSTALS IN THE KNEE JOINTS OF PATIENTS WITH ASYMPTOMATIC NONTOPHACEOUS GOUT
148 MONOSODIUM URATE CRYSTALS IN THE KNEE JOINTS OF PATIENTS WITH ASYMPTOMATIC NONTOPHACEOUS GOUT JOHN S. BOMALASKI, GERONIMO LLUBERAS, and H. RALPH SCHUMACHER, JR. We aspirated synovial fluid from the
More informationClinical Practice Guideline. Gout. Version
Clinical Practice Guideline Gout Version 1.1.2017 August 2017 Table of Contents Introduction...5 Stages of Gout...7 Asymptomatic Hyperuricemia... 7 Acute Intermittent Gout... 7 Advanced Gout... 8 Diagnosis...8
More informationThe 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 6.1.2, 6.2.1, 7.1.2, 7.1.3,
UPDATE ON GOUT Learning objectives: After completing this activity, pharmacists should be able to: 1. describe the mechanisms underlying hyperuricaemia 2. state the risk factors for development of gout
More informationCopyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
14 The Nurse Practitioner Vol. 41, No. 14 www.tnpj.com 2.5 CONTACT HOURS 2.5 CONTACT HOURS Gout An update on for primary care providers Abstract: This article discusses the current beliefs regarding the
More informationuric acid Non electrolytes of the plasma
73 uric acid Non electrolytes of the plasma 1 Purines and uric acid Fig 2 JFI Uric acid is the major product of catabolism of the purine nucleosides adenosine and guanosine, Uric acid is sparingly soluble
More informationLECTURE 5: DRUGS IN GOUT
Red : important Black : in male / female slides Pink : in female s slides only Blue : in male s slides only Green : Dr s notes Grey: Extra information, explanation Editing File LECTURE 5: DRUGS IN GOUT
More informationACR Meeting November, 2012
ACR Meeting November, 212 Arhalofenate is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian
More informationGout basics. Update on Gout. Production of uric acid. Gout basics. Crystal induced inflammation. Gout calculator. The important role of ultrasound
Update on Gout The important role of ultrasound Cheung C Yue, M.D. Gout basics Hyperuricemia gout Over 5 years, 22% >9 mg/dl develop gout Man 3-4 times more than women Risks: thiazide, cyclosporin, low
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 24 June 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 24 June 2009 ADENURIC 80 mg, film-coated tablets B/28 (CIP code: 385 724-4) B/84 (CIP code: 572 820-3) ADENURIC 120
More informationEvidence Based Medicine and the Treatment of Gout
Evidence Based Medicine and the Treatment of Gout DANIEL P. EVANS, DPM, FACFAOM Professor, Department of Podiatric Medicine and Radiology Dr. Wm. Scholl College of Podiatric Medicine GORDON K. LAM, MD,
More informationClinical Policy Bulletin: Gout
Gout Page 1 of 13 Clinical Policy Bulletin: Gout Number: 0810 Policy Aetna considers the following tests medically necessary for the diagnosis of gout: Measurement of blood uric acid levels Measurement
More informationpegloticase (Krystexxa )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOsteoarthritis. Rheumatology Update. Gout 1/17/2013
Osteoarthritis Rheumatology Update Richard Zweig, MD January, 2013 Degeneration of cartilage over time accompanied by increase in bone density and bone formation around the joint Risks include: aging,
More informationGout in the UK and Germany: prevalence, comorbidities and management in general practice
1 IMS Health, Brussels, Belgium; 2 Department of Public Health, Ghent University, Ghent, Belgium; 3 School of Pharmacy, Brussels University, Brussels, Belgium; 4 IMS Health, London, UK; 5 Ipsen, Paris,
More informationFor more information about how to cite these materials visit
Author(s): Seetha Monrad, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationTherapy for Gout: The Past
Advances in Therapy for Gout: 2011 The Past, Present, and Future Therapy for Gout: The Past May 22, 1997 Pity a Tyrannosaur? Sue Had Gout By MALCOLM W. BROWNE Jonathan Graf, M.D. Associate Professor of
More informationFebuxostat now subsidised on Special Authority
Gout update: Febuxostat now subsidised on Special Authority 38 Febuxostat was added to the New Zealand Pharmaceutical Schedule on 1 June, 2014. It is now available as a third-line preventive treatment
More informationOxford Kidney Unit. Dietary advice for managing gout Information for patients
Oxford Kidney Unit Dietary advice for managing gout Information for patients page 2 This leaflet is for you if you are suffering from gout. It will give you information to help manage your symptoms. What
More informationPlus: How to gain control of symptoms A gout-friendly eating style Lifestyle changes that can help prevent future attacks
about Gout What You Need to Know about Gout & Uric Acid Plus: How to gain control of symptoms A gout-friendly eating style Lifestyle changes that can help prevent future attacks We re doing everything
More informationClass Update: Drugs for Gout
Copyright 2012 Oregon State University. ll Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGout FACTSHEET REAL LIFE STORY
1 What is gout? Gout is a type of arthritis where swelling and severe pain develops rapidly in joints, especially at the base of the big toe. Gout affects approximately one in 30 adults, most commonly
More information4/1/2011. New Developments in Gout. Conflict of Interest Declaration. Objectives
New Developments in Gout Tatum N. Mead, Pharm.D. Clinical Assistant Professor UMKC SOP meadt@umkc.edu April 16, 2011 1 Conflict of Interest Declaration I have no actual or potential conflict of interest
More informationGout. Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 CLINICAL REVIEW
Gout Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 1 Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele ST5 5BG, UK 2 Academic Rheumatology, University
More informationLiterature Scan: Analgesics for Gout. Month/Year of Review: April 2015 Date of Last Review: January 2014
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationNew Drug Evaluation: lesinurad tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationARD Online First, published on November 2, 2007 as /ard
ARD Online First, published on November 2, 2007 as 10.1136/ard.2007.076232 Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000 2005 L Annemans, E Spaepen, M Gaskin,
More informationPART MUSCULOSKELETAL DISORDERS
PART 12 MUSCULOSKELETAL DISORDERS CASE STUDY 77 GOUT For the Patient Case for this case study, see the printed book. DISEASE SUMMARY Definitions Gout is a syndrome of abnormal purine (i.e., DNA nucleotide
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationThe Clinic a l Problem
T h e n e w e ngl a nd j o u r na l o f m e dic i n e Gout Tuhina Neogi, M.D., Ph.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various
More informationVI.2 Elements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Febuxostat is a medicine used in adults with gout to reduce high levels of uric acid in the blood. Gout results from a build up
More informationKrystexxa. Krystexxa (pegloticase) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.14 Subject: Krystexxa Page: 1 of 5 Last Review Date: March 16, 2018 Krystexxa Description Krystexxa
More informationJournal of Advanced Scientific Research
Bijoy Kumar Panda et al, J Adv Scient Res, 2012, 3(2): 03-11 3 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Review Article Febuxostat,
More informationTherapy for Gout: The Past
Advances in Therapy for Gout: 2015 The Past, Present, and Future Therapy for Gout: The Past Jonathan Graf, M.D. Professor of Clinical Medicine UCSF Division of Rheumatology, SFGH May 22, 1997 Pity a Tyrannosaur?
More informationMono-articular Joint Complaints
Mono-articular Joint Complaints Derrick J. Todd, M.D., Ph.D. Associate Physician Department of Rheumatology, Immunology, and Allergy Brigham and Women s Hospital Instructor of Medicine Harvard Medical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Krystexxa) Reference Number: CP.PHAR.115 Effective Date: 06.01.13 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationFebuxostat: a safe and effective therapy for hyperuricemia and gout
DRUG EVALUATIO Febuxostat: a safe and effective therapy for hyperuricemia and gout atasha Jordan & Geraldine M McCarthy Author for correspondence Mater Misericordiae University Hospital, Eccles St. Dublin
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More informationGouty arthritis: an approach for general practice
Gouty arthritis: an approach for general practice Abstract Tikly M, MBBCh, PhD, FCP(SA), FRCP, Professor of Rheumatology Makan K, MBChB, FCP(SA), Rheumatology Fellow Division of Rheumatology, Chris Hani
More informationGOUT GO FOR SIX WITH. Everything You Need to Know About Gout & Uric Acid PLUS:
GO FOR SIX WITH Everything You Need to Know About Gout & Uric Acid GOUT PLUS: How to gain control of symptoms A gout-friendly eating style Medication recommendations to discuss with your doctor Lifestyle
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationClinical Biochemistry department/ College of medicine / AL-Mustansiriyah University
Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ABCG2 gene, in gout, 283 285 Acetaminophen, for CPP crystal deposition, 347 ACTH (corticotropin), for gout, 335 336, 383 ADAMTS proteins,
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More information2.0. Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. 24 The Nurse Practitioner Vol. 40, No. 8
2.0 CONTACT HOURS 24 The Nurse Practitioner Vol. 40, No. 8 www.tnpj.com Treatment and gout prevention of o leva Abstract: Gout is a disorder of purine metabolism that primarily occurs in adult males. Elevated
More informationD espite reasonable understanding of its pathogenesis
1312 EXTENDED REPORT EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics
More information